Skip to content

Study · Not a test of the peptide alone · 2016

1 result

Comparative Functional Alanine Positional Scanning of the α-Melanocyte Stimulating Hormone and NDP-Melanocyte Stimulating Hormone Demonstrates Differential Structure-Activity Relationships at the Mouse Melanocortin Receptors.

Todorovic A, Ericson MD, Palusak RD, Sorensen NB, Wood MS, Xiang Z, Haskell-Luevano C

ACS chemical neuroscience17 May 2016Cited by 6 (Europe PMC)

PMID27135265 (opens in a new tab)PMCIDPMC5596636 (opens in a new tab)DOI10.1021/acschemneuro.6b00098 (opens in a new tab)PepBankPUB-27135265
Source linkPubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, Melanotan I (afamelanotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Melanotan I (afamelanotide).

  1. 01LabNot a test of Melanotan I (afamelanotide) aloneIn vitro (cells)Activity measurement

    At cloned mouse melanocortin receptors, potency changes from alanine substitutions in alpha-MSH did not necessarily match those in NDP-MSH analogs.

    In plain wordsIn lab tests, changing single amino acids in alpha-MSH and in NDP-MSH did not always change receptor potency in the same way.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    Not applicablePotency of alanine-substituted NDP-MSH analogs at mouse melanocortin receptors
    Study

    mouse (receptors)n: not reported in source

    cloned mouse melanocortin receptors
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    Importantly, the altered potencies due to Ala substitutions in α-MSH did not necessarily correlate with equivalent Ala substitutions in NDP-MSH, indicating that structural modifications and corresponding biological activities in one of these melanocortin ligands may not be predictive for the other agonist.

    In this study, Melanotan I (afamelanotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan I (afamelanotide).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.